A green-lipped mussel reduces pain behavior and chondrocyte inflammation and attenuated experimental osteoarthritis progression.

The green-lipped mussel (GLM) contains novel omega-3 polyunsaturated fatty acids, which exhibit anti-inflammatory and joint-protecting properties. Osteoarthritis (OA) is a degenerative joint disease characterized by a progressive loss of cartilage; oxidative stress plays a role in the pathogenesis of OA. The objectives of this study were to investigate the in vivo effects of the GLM on pain severity and cartilage degeneration using an experimental rat OA model, and to explore the mode of action of GLM. OA was induced in rats by intra-articular injection of monosodium iodoacetate (MIA) into the knee. Oral GLM was initiated on the day after 3dyas of MIA injection. Limb nociception was assessed by measuring the paw withdrawal latency and threshold. Samples were analyzed both macroscopically and histologically. Immunohistochemistry was used to investigate the expression of interleukin-1β (IL-1β), IL-6, nitrotyrosine, and inducible nitric oxide synthase (iNOS) in knee joints. Also, the GLM was applied to OA chondrocyte, and the expression on catabolic marker and necroptosis factor were evaluated by real-time polymerase chain reaction. Administration of the GLM improved pain levels by preventing cartilage damage and inflammation. GLM significantly attenuated the expression levels of mRNAs encoding matrix metalloproteinase-3 (MMP-3), MMP-13, and ADAMTS5 in IL-1β-stimulated human OA chondrocytes. GLM decreased the expression levels of the necroptosis mediators RIPK1, RIPK3, and the mixed lineage kinase domain-like protein (MLKL) in IL-1β-stimulated human OA chondrocytes. Thus, GLM reduced pain and cartilage degeneration in rats with experimentally induced OA. The chondroprotective properties of GLM included suppression of oxidative damage and inhibition of catabolic factors implicated in the pathogenesis of OA cartilage damage. We suggest that GLM may usefully treat human OA.

Introduction

Osteoarthritis (OA) is the most widespread form of arthritis, which is a dynamic disease of the articular cartilage, the underlying bones, and the synovia of joints. The degenerative disease is characterized by articular cartilage destruction caused by an anabolic/catabolic imbalance imparted by mechanical stress [1,2]. OA features low-grade inflammation. Inflammatory cytokines, chemokines, reactive oxygen species (ROS), and matrix metalloproteinase (MMPs) are released by chondrocytes and related cells in the joints of patients with OA [3-5]. The proinflammatory cytokines and chemokines compromise the homeostasis of the cartilage matrix of OA joints, associated with increased production of interleukin-1β (IL-1β), which induces chondrocytes to produce inflammatory mediators such as nitrotyrosine and IL-6, which further increase the harmful cellular responses [6]. And previously studies have reported the nuclear factor-kappaB (NF-κB) transcription factors as over activated in OA and as a diseases-providing factor [7,8]

Necroptosis (programmed necrosis), a recently recognized form of cell death, triggers serious inflammation [9]. Necroptotic cells feature damage-associated molecular patterns that trigger robust inflammatory responses; necroptosis is markedly more immunogenic than apoptosis, associated with high-level inflammation and extracellular matrix (ECM) degradation [10]. Necroptosis is mediated principally by the receptor interacting protein kinase 1 (RIP1), the receptor interacting protein kinase-3 (RIP3), and the mixed lineage kinase domain-like protein (MLKL) [11,12]. RIP3 expression was increased in patients with OA. Necroptosis inhibitors could serve as OA therapeutics [13].

A green-lipped mussel (GLM) has been prepared from a significant commercial marine species of New Zealand. The GLM is a natural dietary supplement that reduces OA inflammation and arthritis. GLM contains abundant long-chain omega-3 polyunsaturated fatty acids, docosahexaenoic acid (DHA), and many minor fatty acids (including 5, 9, 12, 16-nonadecatetraenoic acid, 5, 9, 12, 15-octadecatetraenoic acid, and 5, 9, 12, 15, 18-heneicosapentaenoic acid) [14]. Many animal and clinical studies have shown that GLM exhibits anti-inflammatory, anti-arthritic, and gastro-protective properties [15-18]. Specifically, long-chain omega-3 polyunsaturated fatty acids such as EPA and DHA are known to exert anti-inflammatory effects. Also, previous study showed that osteoarthritis development is notably associated with oxidative stress and ROS [19,20]. There are many studies of its application in the oral administration of osteoarthritis through anti-inflammatory and antioxidant effects [21,22]. In particular, GLM have antioxidant activity. Bioactive peptides of GLM with the strongest radical scavenging activity and ACE inhibitory activity would supply a therapeutic effect for the osteoarthritis [23].

Given the possible significance of catabolic and necroptotic pathways in OA pathogenesis, and the anti-inflammatory and anti-oxidative effects of GLM, we explored the effects of GLM in an animal model of OA. GLM reduced pain, cartilage destruction, regional catabolism, inflammation, and injury in a rat model of OA. Apart from its chondroprotective effects, GLM inhibited catabolic factors and necroptotic markers involved in OA pathogenesis.

Materials and methods

Animals

Seven-week-old male Wistar rats weighing 180~250 g at the start of the experiment were purchased from Shizuoka Laboratory Center (Shizuoka, Japan). A maximum of three animals per cage were housed in a room featuring controlled temperature (20–26°C) and light (12-h/12-h light/dark cycle) conditions. The rats had free access to a gamma-ray-sterilized diet (Teklad Global 18% Protein Rodent Diet, Harlan Laboratories, Inc., Indianapolis, IN, USA) and autoclaved water. All animal research procedures were conducted in accordance with the Laboratory Animals Welfare Act (Korea), the Guide for the Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experiments of the Institutional Animal Care and Use Committee (IACUC) of the School of Medicine, the Catholic University of Korea. The IACUC and the Department of Laboratory Animals of the Catholic University of Korea, Songeui Campus, accredited the Korean Excellence Animal Laboratory Facility in co-operation with the Korean Food and Drug Administration in 2017 and full accreditation by AAALAC International followed in 2018. All experimental procedures were evaluated and conducted in accordance with the protocols approved by the Animal Research Ethics Committee at the Catholic University of Korea (Permit Number: CUMC 2020-0244-01). All procedures performed in this study followed the ethical guidelines for animal use.

MIA-induced OA

The rats were randomly assigned to treatment groups prior to the beginning of the study. Rats were divided into six groups (6 rats in each group) and were group housed in two cages. Each in vivo experiment was repeated a total 2 times. After anesthetization with isoflurane, the rats were injected with 3 mg monosodium iodoacetate (MIA) (Sigma, St. Louis, MO, USA) dissolved in 50 μL (60 mg/mL) volume using a 26.5-G needle inserted through the patellar ligament into the intra-articular space of the right knee. GLM at 100, 300mg/kg and celecoxib at 50 mg/kg, were administered orally to MIA-injected rats.

Osteoarthritic pain assessment

Nociception in MIA-treated rats was tested using a dynamic plantar aesthesiometer (Ugo Basile, Gemonio, Italy). This is an automated version of the von Frey hair assessment tool and is used to assess mechanical sensitivity. Assessment was conducted by placing each rat on a metal mesh in an acrylic chamber housed in a temperature-controlled room (20–26°C), where the rat rested for 10 min before the touch stimulator unit was positioned under the animal. An adjustable angled mirror was used to place the stimulating microfilament (0.5 mm in diameter) below the plantar surface of the hind paw. When the instrument was activated, the fine plastic monofilament advanced at a constant speed and touched the paw in the proximal metatarsal region. The filament exerted a gradually increasing force on the plantar surface, beginning below the threshold of detection, and increasing until the stimulus became painful, as indicated by the rat’s withdrawal of its paw. The force required to elicit a paw-withdrawal reflex was recorded automatically and measured in g. A maximum force of 50 g and a ramp speed of 25 s were used for all aesthesiometer tests.

Weight balance assessment

The weight balance of MIA-treated rats was analyzed using a capacitance meter (IITC Life Science, Victory Blvd, CA, USA). Each rat was allowed to acclimate for 5 min in an acrylic holder. Then, both feet were fixed to the pad and the weight balance measured over 5 s. This was repeated twice. The weights the unguided and guided legs were calculated and entered into a formula that yielded a percentage; this compared the legs with and without OA.

Histopathological analysis

Knee joints were collected 3 weeks after MIA induction. The tissues were fixed in 10% (v/v) formalin for 24 h, decalcified using Decalcifying Solution-Lite (Sigma) for 72 h, and embedded in paraffin. Sections 5-μm in thickness were cut, dewaxed using xylene, dehydrated through alcohol gradient baths, and stained with safranin O.

Immunohistochemistry

Paraffin-embedded sections were incubated at 4°C with the following primary monoclonal antibodies: Anti-cluster of differentiation (CD)4, anti-CD19, anti-interleukin (IL)-1β, anti-IL-6, anti-inducible nitric oxide synthase (iNOS), anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), anti-matrix metalloproteinase (MMP)-1, and anti-MMP3. The samples were then incubated with the appropriate, secondary biotinylated antibodies, followed by a 30-min incubation with a streptavidin-peroxidase complex. The reaction products were developed using the 3, 3-diaminobenzidine chromogen (Dako, Glostrup, Denmark). Immunohistochemistry evaluations were performed independently by two experienced researchers who were blinded to the study group. The positive cell percentage was analyzed with HDAB (Hematoxylin & DBA) by selecting color deconvolution in the plugin item in the image J program (NIH, MD USA).

Human chondrocyte isolation and differentiation

Human articular cartilage was obtained from five OA patients treated in Uijeongbu St. Mary’s Hospital (UC14CNSI0150) where they underwent knee arthroplasty or joint replacement surgery. All five patients gave fully informed written consent in accordance with the relevant ethical guideline. Chondrocytes were isolated as previously described [24]. Briefly, OA joints were chopped finely and digested with 5 mg/mL protease at 36°C for 1 h and then with 2 mg/mL collagenase and 0.5 mg/mL hyaluronidase (all from Sigma-Aldrich) for 3 h. After several subcultures, chondrocytes below passage 5 were seeded at 5x104 cells/well into 24-well plates. Following 24 h of starvation, the chondrocytes were stimulated with 20 ng/mL IL-1β or various concentrations of GLM (10, 100, 250 μg/mL) in serum-free Dulbecco’s Modified Eagle’s Medium (DMEM) for 48 h. The supernatants and cell layers were collected for further analyses.

Enzyme-linked immunosorbent assays (ELISAs)

The concentrations of IL-6 and MCP-1 in cell supernatants were measured using sandwich ELISAs (Duoset; R&D Systems, Minneapolis, MN, USA). After color development, the absorbance was measured at 405 nm on an ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Real-time Polymerase Chain Reaction (PCR)

Total RNA was isolated from human chondrocytes with the aid of the TRI reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer’s instructions and reverse-transcribed using a first-strand cDNA synthesis kit (Takara, Shiga, Japan). qPCR was performed with the aid of a LightCycler 2.0 instrument (Roche Diagnostics Indianapolis, IN, USA; software version 4.0) and the SensilFAST SYBR Kit (Bioline, Cincinnati, OH, USA). The housekeeping β-actin gene served as the normalization control. The primer sequences were as follows: β-actin, forward 5′-GGACTTCGAGCAAGAGATGG-3′, reverse 5′-TGTGTTGGGGTACAGGTC TTTG-3′; MMP3 forward: 5′-CTCACAGACCTGACTCGGTT-3′, reverse 5′-CACGCCTGAAGGAAGAGA TG-3′; MMP13 forward: 5′-CTATGGTCCAGGAGATGAAG-3′, reverse 5′-AGAGTCTTGCCTGTATCCTC-3′; MCP1 forward 5′-CAGCCAGATGCAATCAATGC-3′, reverse 5′-GTGGTCCATGGAATCCTGAA-3’, MLKL forward 5′-GCAAGCTGGTGGCTGTGAAGC-3′, reverse 5′-TTCATCCACAGAGGGCCGCA-3′; and RIPK1 forward 5′-GACGAAGCCAACTACCATCTT-3′, reverse 5′-TCTCCTTTCCTCCTCTCTGTT-3′; RIPK3 forward 5′-ATGTCGTGCGTCAAGTTATGG-3′, reverse 5′-CGTAGCCCCACTTCCTATGTTG-3′;

CCK8 assay

Chondrocyte proliferation was measured using the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) as previously described [25]. Chondrocytes were seeded into 96-well plates at 1x104 cells/well. Cells were pre-incubated for 24 h in serum-free DMEM with the Insulin-Transferrin Selenium-A (ITSA) solution (ThermoFisher, Waltham, MA, USA) followed by stimulation with 20 ng/mL IL-1β or GLME (10, 100, 250 μg/mL) for 48 h. Cells were supplemented with the CCK-8 solution for another 3 h at 37°C and the OD450 measured using a microplate reader (Molecular Devices).

Statistical analysis

Statistical analyses were performed using the nonparametric Mann-Whitney U-test for comparisons between two groups, and one-way ANOVA with the Bonferroni post-hoc test for multiple comparisons. GraphPad Prism (ver. 5.01; GraphPad Software Inc., San Diego, CA, USA) was used for all analyses. The data are presented as means ± standard deviations (SDs). For all comparisons, P < 0.05 was taken to indicate statistical significance.

Results

GLM regulates the pain threshold

The pain-killing capacity of GLM was analyzed; pain was quantified using the electronic von Frey system. Weight bearing was assessed employing a capacitance meter. Three weeks after MIA injection into the right knees, we found that the paw withdrawal latency and withdrawal threshold were dose-dependently reduced by GLM compared to the vehicle (Fig 1A and 1B); GLM also improved the weight balance (Fig 1C).

Fig 1

Green-lipped mussel extract reduced pain in MIA-injected rats.

(A) Schedule of rat experimental procedure is shown by a diagram. (B) Pain was analyzed as the difference between the PWL (left) and PWT (right) in vehicle-treated MIA-induced OA rats, and those given GLME orally. Rats with MIA-induced OA (n = 6 per group) were evaluated to day 21. Nociceptive testing was performed using a dynamic plantar esthesiometer; this is an automated version of the von Frey hair assessment tool. (C) Weight-bearing was examined (n = 6 per group) today 28. Data are presented as the means ± SDs of those of three independent experiments. Significant differences were evident between the vehicle- and GLME-treated groups. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the vehicle-treated group.

GLM suppresses cartilage destruction and inflammation in the rat model of MIA-induced OA

We collected the right knee joints 3 weeks after MIA injection and used safranin O staining for histopathological analysis. GLM dose-dependently reduced cartilage damage and proteoglycan depletion (Fig 2A) as assessed by OARSI and Mankin scoring (Fig 2B). Immunohistochemistry confirmed the presence of inflammatory mediators and the aging factor. Rheumatoid arthritis-like synovitis was observed after OA induction (Figs 2C and 3A). The T- and B-cell immune responses were reduced by GLM at 300 mg/kg compared to the vehicle, as were the levels of IL-1β, IL-6, iNOS, and NF-κB (Figs 2D and 3B).

Fig 2

Histological evaluation of joints after oral administration of GLME to rats with MIA-induced OA.

Rats were injected with 3 mg of monosodium iodoacetate (MIA) (into the right knee). GLME was given orally every day from day 3 after MIA injection. The joints were resected on day 21 after MIA injection. (A) Knee joints from the OA rats. Joint samples were acquired from the WT, vehicle, GLM (100 mg/kg, 300 mg/kg) and Celecoxib (50 mg/kg) groups and stained with hematoxylin and eosin (original magnification x 200). (B) The OA lesions were graded on a scale of 0–13 using the modified Mankin scoring system that evaluates structure, cellular abnormalities, and matrix staining. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the MIA-injection group. (C) CD4 and CD19 expression levels in the synovia of OA rats as revealed immunohistochemically 21 days after MIA injection. Immunohistochemistry was used to evaluate representative sections of joints from MIA-injected rats given GLM, celecoxib, or the vehicle. Positive cells stain brown; the nuclei were counterstained with hematoxylin. The bar graphs represent the means ± SDs of the numbers of stained cells. *P < 0.05, **P < 0.01 compared to the MIA-injection group.

Fig 3

Effects of GLME on the expression levels of IL-1β, IL-6, iNOS, and NF-kB in the synovia of OA joints.

(A) Immunohistochemical staining for IL-1β, IL-6, iNOS, and NF-kB after oral administration of GLME daily for 21 days after MIA injection. (B) The positive cells stain brown; the nuclei were counterstained with hematoxylin. Slides of representative sections showing expression of IL-1β, IL-6, iNOS, and NF-kB. *P < 0.05, **P < 0.01 compared to the MIA-injection group.

GLM regulates the expression of catabolic enzymes and pro-inflammatory cytokines in human OA chondrocytes

We used immunohistochemistry to explore the levels of catabolic factors. We previously found that GLM inhibited cartilage destruction. We confirmed that GLM regulated the levels of catabolic factors (Fig 4A). The MMP-1 and MMP-3 levels were reduced by treatment with GLM (300 mg/kg) (Fig 4B). We explored whether GLM regulated catabolic gene expression in OA chondrocytes. We found that the levels of mRNAs encoding MMP3 and MMP13 (ECM degradation proteins of articular cartilage) were significantly downregulated in the GLME compared to the control group (Fig 4C). In addition, the level of MCP-1, which chemoattracts macrophages, was also decreased by GLM treatment (Fig 4C). The concentrations of IL-6 and MCP-1 in culture supernatants were also reduced by GLM (Fig 4D). To control for possible GLM cytotoxicity, we performed the CCK-8 assay. GLM (10 μg/mL, 100 μg/mL) did not affect the proliferation of OA chondrocytes (Fig 4E).

Fig 4

Reductions in the levels of catabolic markers and inflammatory cytokines in OA rats and human chondrocytes.

(A, B) Immunohistochemical staining was used to identify MMP1 and MMP3. (C) qRT-PCR analysis of the levels of mRNAs encoding MMP3, MMP13 and MCP-1 in IL-1β (20 ng/mL)-stimulated OA chondrocytes in the presence or absence of (various concentrations of) GLME (10, 100, 250 μg/mL) and Celecoxib (10 μM). (D) IL-6 and MCP-1 levels in cell supernatants were measured via sandwich ELISAs. (E) OA chondrocyte cell viability in the presence or absence of GLME, as revealed by the CCK8 assay. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the vehicle-treated group.

GLM inhibits inflammatory cell death of human OA chondrocytes

We next tested whether GLM modulated necroptosis of human OA chondrocytes, as was true of the cells in MIA-induced OA cartilage tissue. We immunohistochemically stained for RIP1, RIP3, and pMLKL (markers of necroptosis) to determine whether the anti-nociceptive effect of GLM reflected an anti-necroptosis activity, perhaps explaining the protective effect of GLM in terms of structural damage to knee joints. Synovial RIP1, RIP3 and pMLKL staining were reduced in the GLM group (Fig 5A and 5B). We next stimulated human OA chondrocytes with IL-1β, with or without GLM, and found that the transcriptional levels of RIPK1, RIPK3, and MLKL were substantially suppressed by GLME, consistent with the immunohistochemical data (Fig 5C).

Fig 5

Reduced levels of necroptosis-related markers in OA rats and human chondrocytes.

(A, B) Representative immunohistochemical staining of RIP1, RIP3, and pMLKL in the synovia of non-OA rats (WT), vehicle-treated MIA-induced OA rats, and GLME-treated MIA-induced OA rats. (C) The levels of mRNAs encoding necroptotic marker genes (as revealed by real-time PCR) in human OA chondrocytes treated with IL-1β (20 ng/mL) and then co-cultured with GLME or celecoxib. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the vehicle-treated group.

Discussion

Of the various dietary supplements, GLM is favored by patients with OA. Several clinical studies have reported good results [26]. We found that GLM reduced the clinical and histological scores of rats with MIA-induced OA. GLM significantly reduced pain, inflammatory cell infiltration, and the adverse histopathological changes. Thus, GLM simultaneously controlled OA pain and protected cartilage.

Articular cartilage degeneration is a major clinical feature of OA [27]. OA is not entirely a degenerative disease, being partly an inflammatory condition involving the actions of IL-1β, IL-6, and nitrotyrosine [28]. We found that GLM reduced cartilage injury and pain in the subchondral bone and the articular cartilage. IL-1β and IL-6 expression decreased significantly after GLM administration. The expression of iNOS was inhibited after GLME administration. The iNOS expression level reflects the NO content of OA joints. The role of NO in OA pathogenesis has recently been reported in detail [29]. In OA patients, control of oxidative stress is of therapeutic importance. This suggests that the reduced cartilage degradation in response to GLM was, in part, attributable to a lessening of oxidative damage and attenuated production of proinflammatory cytokines.

Persistent low-rate oxidative stress is a fundamental feature of OA pathology [30]. Increases in age-related oxidative stress render human chondrocytes susceptible to oxidant-mediated apoptosis via dysregulation of the antioxidant system [31]. Other forms of oxidative stress boost NO production, inducing aberrant apoptosis of human chondrocytes mediated via mitochondrial dysfunction [32]. MIA, a blocker of glyceraldehyde-3-phosphate dehydrogenase, generates OA-like lesions in rat joints because of cartilage degradation resembling that of human OA [33,34]. Turning to the significance of ROS and mitochondrial functional disorders in human OA, MIA-induced chondrocyte apoptosis has recently been reported to involve mitochondrial pathways including those responsible for ROS production and caspase activation [35]. These findings support the suggestion that the MIA model fairly reflects human OA; the cartilage breakdown mechanisms are similar. In our rat OA model, GLM reduced pain and eliminated the mitochondrial dysfunction caused by MIA.

Several recent reports have demonstrated the osteoarthritis therapeutic effectiveness of the administration of natural compound. Dietary supplementation with Palmitoyl-Glucosaine with curcumin decreased MIA-induced secondary allidynia at either threshold of latency level. Also, PGA-Cur with significantly decrease in serum levels of TNF-α, IL-1β, NGF as well as metalloproteases 1,3, and 9 [36]. In addition, there are studies on pain and inflammation ameliorate in osteoarthritis disease studies using natural compounds such as cashew nut, hyaluronic acid, and ALIAmide palmitoylglucosamine [21,22,37,38]. Also, in our studies GLM ameliorate pain and cartilage destruction in monosodium iodoacetate induced OA. The chondroprotective effects of GLM implicated inhibition of oxidative damage and suppression of catabolic factors involved in the pathogenesis of OA cartilage damage. But, further studies are need to further elucidate the relationship between natural compound and therapeutic effect of osteoarthritis.

The chondroprotective effects correlated strongly with catabolic inhibition of the articular cartilage matrix. The levels of specific markers of cartilage destruction, including MMP1, MMP3, and MMP13, were significantly decreased following GLM treatment of both rats and human OA chondrocytes. These valuable properties of GLM also delayed OA development, suggesting that the effects may be significant throughout the various stages of disease.

Many studies have explored whether necroptosis inhibitors suppress cell death [39]. Necroptosis is significant in terms of inflammatory disease development. To the best of our knowledge, this is the first study to investigate the anti-necroptotic properties of GLME using both an animal model and human OA chondrocytes. GLM was decrease the levels of necroptotic mediators in the synovium of rats. GLM may attenuate the inflammatory response by inhibiting necroptosis.

GLME reduced NF-κB expression in rat joints. GLM controlled the levels of upstream mediators that modulate the expression of inflammatory cytokines. Thus, the anti-inflammatory effects of GLM may reflect reduced NF-κB activation. Further molecular characterization of the relevant factors is required.

In conclusion, To the best of our knowledge, this study is the first to demonstrate the potential of GLM as an OA therapeutic agent. MIA-induced arthritis was decreased by GLM, which inhibited catabolism, and the expression of proinflammatory cytokines and mediators of necroptosis. GLM may usefully prevent OA. Our data will aid OA patients who seek valuable natural products. GLM may be a useful OA therapeutic.

7 May 2021

PONE-D-21-07398

A Green-lipped mussel reduces pain behavior and chondrocyte inflammation and attenuated experimental osteoarthritis progression

PLOS ONE

Dear Dr.

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 10 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Rosanna Di Paola, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

"NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

If any authors received a salary from any of your funders, please state which authors and which funders.

If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We noticed you have some minor occurrence of overlapping text with the following previous publication, which needs to be addressed:

- https://synapse.koreamed.org/articles/1033447

The text that needs to be addressed involves the Introduction section.

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper by JooYeon Jhun et al, describes the anti-inflammatory and joint-protecting properties of green-lipped mussel in a in vivo model of MIA.

The rational behind the experiment was clear and straight forward. The manuscript is almost well written

I recommend that the paper be accepted with minor revision:

a) The authors should better check the manuscript for any typographical errors.

b) The authors should clarify in the Materials and methods section the experimental groups and the experimental conditions.

c) The discussion does a good job at explaining the importance of the results in the context of the inflammatory pathways involved. However, incorporation of previous results from other related studies with natural compound is lacking such as 10.3390/ani10101827 or 10.3390/antiox9060511 or 10.1186/s13075-016-1189-5 or 10.1186/s13075-019-2048-y or 10.1155/2021/5534614 or 10.3390/antiox10020265

d) please provide high magnification of figure 2,3,4 and 5 to better understand the signal maybe as supplementary files and better clarify the method for IHC quantification

Reviewer #2: The manuscript by JooYeon Jhun al ” A Green-lipped mussel reduces pain behavior and chondrocyte

inflammation and attenuated experimental osteoarthritis progressionnts”

The manuscript is interesting in its field, showing an overview of the GLM use in osteoarthritis progressionnts.

I recommend major revision for the paper:

• The authors should improve the english language

• The author should update the bibliography. For example in the introduction the author should insert several paper about the anti inflammatory and antioxidative application of compound present in diet(doi.org/10.3390/antiox9060511;oi.org/10.1186/s13075-019-2048-y)

• the authors should indicate the experimental design through a temporal sequence, clearly indicating the administrations and tests carried out

• The authors should increase the quality of the images, for example in figure 2C, the photos appear to have been taken in different places

• Is there a mechanism of action for GLM? The authors speak of a mediated NfkB mechanism, has a mechanism directly linked to GLM been hypothesized?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

5 Oct 2021

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data?e.g. participant privacy or use of data from a third party?those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper by JooYeon Jhun et al, describes the anti-inflammatory and joint-protecting properties of green-lipped mussel in a in vivo model of MIA.

The rational behind the experiment was clear and straight forward. The manuscript is almost well written

I recommend that the paper be accepted with minor revision:

a) The authors should better check the manuscript for any typographical errors.

Answers: Thank you for your comments. As you mentioned that we checked error and typographical.

b) The authors should clarify in the Materials and methods section the experimental groups and the experimental conditions.

Answers: Thank you for your comments. Osteoarthritis was induced in Wistar rat (n=6). The experiment was performed two times. We revised the Material and method section (marker by red color, Page 6, line 21-23)

The rats were randomly assigned to treatment groups prior to the beginning of the study. Rats were divided into six groups (5 rats in each group) and were group housed in two cages. Each in vivo experiment was repeated a total 2 times.

c) The discussion does a good job at explaining the importance of the results in the context of the inflammatory pathways involved. However, incorporation of previous results from other related studies with natural compound is lacking such as 10.3390/ani10101827 or 10.3390/antiox9060511 or 10.1186/s13075-016-1189-5 or 10.1186/s13075-019-2048-y or 10.1155/2021/5534614 or 10.3390/antiox10020265

Answers: Thank you for valuable suggestion. This comment added the discussion section. (marker by red color, Page 14, line 4-15)

Several recent reports have demonstrated the osteoarthritis therapeutic effectiveness of the administration of natural compound. Dietary supplementation with Palmitoyl-Glucosaine with curcumin decreased MIA-induced secondary allidynia at either threshold of latency level. Also, PGA-Cur with significantly decrease in serum levels of TNF-�, IL-1�, NGF as well as metalloproteases 1,3, and 9 [36]. In addition, there are studies on pain and inflammation ameliorate in osteoarthritis disease studies using natural compounds such as cashew nut, hyaluronic acid, and ALIAmide palmitoylglucosamine [21, 22, 37, 38]. Also, in our studies GLM ameliorate pain and cartilage destruction in monosodium iodoacetate induced OA. The chondroprotective effects of GLM implicated inhibition of oxidative damage and suppression of catabolic factors involved in the pathogenesis of OA cartilage damage. But, further studies are need to further elucidate the relationship between natural compound and therapeutic effect of osteoarthritis.

d) please provide high magnification of figure 2,3,4 and 5 to better understand the signal maybe as supplementary files and better clarify the method for IHC quantification

Answers: Thank you for your comment. All images have been replaced with high magnification. Immunohistochemistry evaluations were performed independently by two experienced researchers who were blinded to the study groups. The positive cell percentage was analyzed with HDAB (Hematoxylin & DAB) by selecting color deconvolution in the plugin item in the image J program (NIH, MD ,USA). We revised the Material and method section (marker by red color, Page 8, line 15 -18 )

Reviewer #2: The manuscript by JooYeon Jhun al " A Green-lipped mussel reduces pain behavior and chondrocyte

inflammation and attenuated experimental osteoarthritis progressionnts"

The manuscript is interesting in its field, showing an overview of the GLM use in osteoarthritis progressionnts.

I recommend major revision for the paper:

? The authors should improve the english language

Answers: Thank you for your comment. The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see:

http://www.textcheck.com/certificate/qUhLlk

? The author should update the bibliography. For example in the introduction the author should insert several paper about the anti-inflammatory and antioxidative application of compound present in diet(doi.org/10.3390/antiox9060511;oi.org/10.1186/s13075-019-2048-y)

Answers: Thank you for your comment. Thanks for suggesting a great article and we’ve added the contents of the article on introduction. (marked by red color, page 6, line 12-14), (marked by red color, page 4, line 5-10)

Also, previous study showed that osteoarthritis development is notably associated with oxidative stress and ROS [19, 20]. There are many studies of its application in the oral administration of osteoarthritis through anti-inflammatory and antioxidant effects [21, 22]. In particular, GLM have antioxidant activity. Bioactive peptides of GLM with the strongest radical scavenging activity and ACE inhibitory activity would supply a therapeutic effect for the osteoarthritis [23].

? the authors should indicate the experimental design through a temporal sequence, clearly indicating the administrations and tests carried out

Answers: Thanks for your comment. We agree with your comments. This comment added the Figure 1.

The protocol for monosodium iodoacetate induced osteoarthritis and ? The authors should increase the quality of the images, for example in figure 2C, the photos appear to have been taken in different places

Answers: Thank for your comments. We agree with your opinions. All images have been replaced with high magnification. As you mentioned, these images are synovium, not a cartilage. Imaging synovium makes it difficult to identify differences in immunohistochemistry in cartilage because the Monosodium Iodoacetate Arthritis model affects cartilage destruction and chondrocyte death. Also, synovitis symptoms appeared due to the characteristics of the MIA models, so Immunohistochemistry was performed in synovium. The quality of the image has been increased. In addition, a separate enlarged shot is included in the image so that you can see it clearly.

? Is there a mechanism of action for GLM? The authors speak of a mediated NfkB mechanism, has a mechanism directly linked to GLM been hypothesized?

Answers: Thanks for pointing out this and we’ve added other taxa following your suggestion. (marked by red color, page 4, line 11-13)

And previously studies have reported the nuclear factor-kappaB (NF-�B) transcription factors as over activated in OA and as a diseases-providing factor [7, 8]

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Submitted filename: rebuttal letter_GLM.docx

Click here for additional data file.

14 Oct 2021

A Green-lipped mussel reduces pain behavior and chondrocyte inflammation and attenuated experimental osteoarthritis progression

PONE-D-21-07398R1

Dear Dr.

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Rosanna Di Paola, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

23 Nov 2021

PONE-D-21-07398R1

A Green-lipped mussel reduces pain behavior and chondrocyte inflammation and attenuated experimental osteoarthritis progression.

Dear Dr. Cho:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Rosanna Di Paola

Academic Editor

PLOS ONE